Monitoring the effects and managing the side effects of anticoagulation during pregnancy.
LMWHs are the major anticoagulant/antithrombotic treatment given to pregnant women to prevent and treat venous thromboembolism despite the absence of specific clinical trials. An emerging indication, the prevention of adverse pregnancy outcomes, is under investigation. During pregnancy, LMWHs seem to be safe and efficient. Some uncertainties remain about the management of rare potential side effects, particularly in the event of heparin intolerance and with cross-reactivity to danaparoid sodium.
Gris
Jean-Christophe
JC
Laboratoire d'Hématologie, Centre Hospitalo-Universitaire, Groupe Hospitalo-Universitaire Caremeau, place du Pr. Robert Debré, F-30029 Nîmes cédex 9, France. jean-christophe.gris@chu-nimes.fr
Lissalde-Lavigne
Géraldine
G
Quére
Isabelle
I
Marés
Pierre
P
D000014:Abnormalities, Drug-Induced; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D000075202:Contraindications; D017449:Dermatitis, Allergic Contact; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy* / Q000517:prevention & control*; D013921:Thrombocytopenia / Q000139:chemically induced; D019851:Thrombophilia / Q000188:drug therapy* / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014812:Vitamin K; D006493:Heparin